200 related articles for article (PubMed ID: 36909163)
1. A small molecule inhibitor of Notch1 modulates stemness and suppresses breast cancer cell growth.
Saran U; Chandrasekaran B; Tyagi A; Shukla V; Singh A; Sharma AK; Damodaran C
Front Pharmacol; 2023; 14():1150774. PubMed ID: 36909163
[TBL] [Abstract][Full Text] [Related]
2. NDR1 increases NOTCH1 signaling activity by impairing Fbw7 mediated NICD degradation to enhance breast cancer stem cell properties.
Wang LL; Wan XY; Liu CQ; Zheng FM
Mol Med; 2022 May; 28(1):49. PubMed ID: 35508987
[TBL] [Abstract][Full Text] [Related]
3. ASR490, a Small Molecule, Overrides Aberrant Expression of
Tyagi A; Chandrasekaran B; Kolluru V; Baby BV; Sripathi CA; Ankem MK; Ramisetti SR; Chirasani VR; Dokholyan NV; Sharma AK; Damodaran C
Mol Cancer Ther; 2020 Dec; 19(12):2422-2431. PubMed ID: 33087513
[No Abstract] [Full Text] [Related]
4. BRD4/nuclear PD-L1/RelB circuit is involved in the stemness of breast cancer cells.
Kim SL; Choi HS; Lee DS
Cell Commun Signal; 2023 Nov; 21(1):315. PubMed ID: 37924094
[TBL] [Abstract][Full Text] [Related]
5. Corrigendum: A small molecule inhibitor of Notch1 modulates stemness and suppresses breast cancer cell growth.
Saran U; Chandrasekaran B; Tyagi A; Shukla V; Singh A; Sharma AK; Damodaran C
Front Pharmacol; 2024; 15():1420266. PubMed ID: 38860169
[TBL] [Abstract][Full Text] [Related]
6. Corrigendum: A small molecule inhibitor of Notch1 modulates stemness and suppresses breast cancer cell growth.
Saran U; Chandrasekaran B; Tyagi A; Shukla V; Singh A; Sharma AK; Damodaran C
Front Pharmacol; 2023; 14():1207589. PubMed ID: 37205914
[TBL] [Abstract][Full Text] [Related]
7. The expression and significance of insulin-like growth factor-1 receptor and its pathway on breast cancer stem/progenitors.
Chang WW; Lin RJ; Yu J; Chang WY; Fu CH; Lai A; Yu JC; Yu AL
Breast Cancer Res; 2013 May; 15(3):R39. PubMed ID: 23663564
[TBL] [Abstract][Full Text] [Related]
8. HES1-mediated inhibition of Notch1 signaling by a Gemini vitamin D analog leads to decreased CD44(+)/CD24(-/low) tumor-initiating subpopulation in basal-like breast cancer.
So JY; Wahler J; Das Gupta S; Salerno DM; Maehr H; Uskokovic M; Suh N
J Steroid Biochem Mol Biol; 2015 Apr; 148():111-21. PubMed ID: 25541438
[TBL] [Abstract][Full Text] [Related]
9. Silencing NOTCH signaling causes growth arrest in both breast cancer stem cells and breast cancer cells.
Suman S; Das TP; Damodaran C
Br J Cancer; 2013 Nov; 109(10):2587-96. PubMed ID: 24129237
[TBL] [Abstract][Full Text] [Related]
10. Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy.
Pham PV; Phan NL; Nguyen NT; Truong NH; Duong TT; Le DV; Truong KD; Phan NK
J Transl Med; 2011 Dec; 9():209. PubMed ID: 22152097
[TBL] [Abstract][Full Text] [Related]
11. Hsp27 participates in the maintenance of breast cancer stem cells through regulation of epithelial-mesenchymal transition and nuclear factor-κB.
Wei L; Liu TT; Wang HH; Hong HM; Yu AL; Feng HP; Chang WW
Breast Cancer Res; 2011 Oct; 13(5):R101. PubMed ID: 22023707
[TBL] [Abstract][Full Text] [Related]
12. miR-638 represses the stem cell characteristics of breast cancer cells by targeting E2F2.
Lin QY; Wang JQ; Wu LL; Zheng WE; Chen PR
Breast Cancer; 2020 Jan; 27(1):147-158. PubMed ID: 31410735
[TBL] [Abstract][Full Text] [Related]
13. Bioinformatics and
Hermawan A; Ikawati M; Khumaira A; Putri H; Jenie RI; Angraini SM; Muflikhasari HA
Adv Pharm Bull; 2021 Feb; 11(2):351-360. PubMed ID: 33880358
[No Abstract] [Full Text] [Related]
14. Upregulated SCUBE2 expression in breast cancer stem cells enhances triple negative breast cancer aggression through modulation of notch signaling and epithelial-to-mesenchymal transition.
Chen JH; Kuo KT; Bamodu OA; Lin YC; Yang RB; Yeh CT; Chao TY
Exp Cell Res; 2018 Sep; 370(2):444-453. PubMed ID: 29981340
[TBL] [Abstract][Full Text] [Related]
15. Sinomenine hydrochloride suppresses the stemness of breast cancer stem cells by inhibiting Wnt signaling pathway through down-regulation of WNT10B.
Li X; Chen W; Huang L; Zhu M; Zhang H; Si Y; Li H; Luo Q; Yu B
Pharmacol Res; 2022 May; 179():106222. PubMed ID: 35413424
[TBL] [Abstract][Full Text] [Related]
16. β1,4-Galactosyltransferase V Modulates Breast Cancer Stem Cells through Wnt/β-catenin Signaling Pathway.
Tang W; Li M; Qi X; Li J
Cancer Res Treat; 2020 Oct; 52(4):1084-1102. PubMed ID: 32599982
[TBL] [Abstract][Full Text] [Related]
17. Targeting treatment-resistant breast cancer stem cells with FKBPL and its peptide derivative, AD-01, via the CD44 pathway.
McClements L; Yakkundi A; Papaspyropoulos A; Harrison H; Ablett MP; Jithesh PV; McKeen HD; Bennett R; Donley C; Kissenpfennig A; McIntosh S; McCarthy HO; O'Neill E; Clarke RB; Robson T
Clin Cancer Res; 2013 Jul; 19(14):3881-93. PubMed ID: 23741069
[TBL] [Abstract][Full Text] [Related]
18. Genetic profiling of different phenotypic subsets of breast cancer stem cells (BCSCs) in breast cancer patients.
Zekri AN; Bahnassy A; Mourad M; Malash I; Ahmed O; Abdellateif MS
Cancer Cell Int; 2022 Dec; 22(1):423. PubMed ID: 36585652
[TBL] [Abstract][Full Text] [Related]
19. Lentivirus-mediated shRNA targeting Nanog inhibits cell proliferation and attenuates cancer stem cell activities in breast cancer.
Hu C; Xu L; Liang S; Zhang Z; Zhang Y; Zhang F
J Drug Target; 2016; 24(5):422-32. PubMed ID: 26339994
[TBL] [Abstract][Full Text] [Related]
20. ALDH1+ stem cells demonstrate more stem cell-like characteristics than CD44
Chen J; Liu S; Su Y; Zhang X
Transl Cancer Res; 2020 Mar; 9(3):1652-1659. PubMed ID: 35117513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
